Innovative Awards for Lung Cancer Research
Three grants have been awarded to early career investigators focusing on innovative approaches for treating HER2-mutated lung cancer, marking a significant step forward in this field.
Understanding HER2 Mutations
The 2025 LCRF | Boehringer Ingelheim Early Investigator Award on Innovative Approaches Toward the Treatment of HER2-Driven Lung Cancer emphasizes the urgent need to explore the role of HER2 mutations in cancer progression. Projects awarded aim to elucidate the mechanisms by which HER2 alterations influence tumor behavior, therapeutic responses, and resistance mechanisms.
Importance of Early-Stage Research
"Identifying actionable targets is crucial for improving treatment responses," says LCRF's Chief Scientific Officer, Dr. Antoinette Wozniak. The hope is that the research funded will lead to tangible advancements in care for patients with HER2-altered cancers.
Celebrating Early Career Scientists
According to Bjoern Rueter, U.S. Vice President at Boehringer Ingelheim, fostering early-career scientists is essential for breakthroughs in medicine. The partnership between LCRF and Boehringer aims to harness diverse perspectives, driving innovation in the fight against lung cancer.
Recognition of Award Recipients
This year, recipients have been recognized for their outstanding research proposals, showcasing valuable insights into HER2-driven lung cancer:
Pinar Özden Eser, PhD
Broad Institute of MIT and Harvard
Identifying actionable targets to improve response to therapy among patients with HER2-driven NSCLC.
Elizabeth Brunk, PhD
The University of North Carolina at Chapel Hill
Linking Structural DNA Variation to Therapeutic Response and Resistance in HER2-Mutated NSCLC.
Paul Stockhammer, MD, PhD
Yale University
Molecular determinants of tumor growth and therapeutic response in ERBB2-mutant lung cancer.
Funding Breakthroughs in Cancer Research
In 2025, LCRF achieved a historic milestone, funding 19 projects worth a total of $4.45 million, thanks to its generous supporters. Initiatives like these are vital for nurturing scientific talent, especially amid a challenging funding landscape.
Dr. Kathryn O'Donnell, chair of the LCRF Scientific Advisory Board, noted the importance of funding for early-career investigators as it preserves the momentum crucial for research advancements in lung cancer.
About the Lung Cancer Research Foundation (LCRF)
The Lung Cancer Research Foundation (LCRF) stands at the forefront of promoting high-impact research designed to enhance survival and quality of life for lung cancer patients. With an impressive history of funding 445 research grants totaling nearly $53 million, LCRF is committed to transforming the future of lung cancer treatment.
Contact Information
For inquiries regarding the awards and research initiatives, please reach out to:
Sheila Sullivan, Sr. Director, Marketing & Communications,
Lung Cancer Research Foundation
Boehringer Ingelheim pursues excellence through its ongoing commitment to innovative cancer treatments. With a focus on collaborative efforts, they aim to revolutionize care for cancer patients.
Frequently Asked Questions
What is the LCRF | Boehringer Ingelheim Early Investigator Award?
The award supports early career researchers developing novel approaches to treat HER2-driven lung cancer.
How much funding do recipients receive?
Each awarded researcher receives a grant of $250,000 for a two-year period to support their projects.
Why is research on HER2 mutations important?
Research on HER2 mutations is critical as these alterations can drive cancer progression and affect treatment responses.
Who are the award recipients for this year?
The recipients for 2025 include Pinar Özden Eser, Elizabeth Brunk, and Paul Stockhammer, recognized for their significant research proposals.
How can I support LCRF's mission?
Support can be provided through donations or by spreading awareness about lung cancer research and its importance.
